Alendronate Versus Denosumab in Kidney Transplant Patients
Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The management of bone disease has often been neglected post-transplantation, when the
clinical focus is on allograft function and immunological sequelae. However, most renal
transplant recipients (RTRs) have pre-existing CKD-MBD, which results in changes to mineral
metabolism and reduced bone mineral density (BMD) and quality, which are linked to an
increased incidence of fractures and cardiovascular disease. Bone loss is greatest in the
first 6-12 months post-transplantation, during which period any intervention is likely to be
of greatest benefit. Anti-resorptive agents all inhibit bone resorption. Since
bisphosphonates and densoumab are the most widely used anti-resorptive agents for
osteoporosis, we conduct this prospective interventional comparative study to compare the
efficacy and tolerability of alendronate versus denosumab in de novo kidney transplant
recipients with reduced bone mineral density, in the first 12 months treatment after kidney
transplantation.